Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.26997 ↗At a glance
Leserbrief in Pediatric Pulmonology, 2024. Written by Emily Mitchell and 1 co-authors. Institution: Department of Pulmonology, University of Virginia, Charlottesville, Virginia, USA. Major MEDLINE topics: Benzodioxoles, Cystic Fibrosis Transmembrane Conductance Regulator, Indoles, Cystic Fibrosis. Cited 2 times so far (Crossref); 5 references. Funded by: None.
Abstract (original language)
The authors declare no conflict of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pulmonology, University of Virginia, Charlottesville, Virginia, USA.
ORCID profiles: Emily Mitchell, Dana Albon
Funding
- None
Cite
APA
Mitchell, E., & Albon, D. (2024). Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26997
Vancouver
Mitchell E, Albon D. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants. Pediatric Pulmonology. 2024. doi:10.1002/ppul.26997
BibTeX
@article{Mitchell2024,
author = {Mitchell, Emily and Albon, Dana},
title = {Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.26997}
}
EUVIMED